Evidence map›Paper›PMID 28714966›Full record

ArticleNature biotechnology2017

Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy.

Yongxin Zhao, Octavian Bucur, Humayun Irshad, Fei Chen, Astrid Weins, Andreea L Stancu, Eun-Young Oh, Marcello DiStasio, Vanda Torous, Benjamin Glass and 4 more

Open access · greenAbstract read
In one paragraph

Article in Nature biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 239 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Yongxin ZhaoMIT Media Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Octavian BucurDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Humayun IrshadDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Fei ChenMIT Media Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Astrid WeinsDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Andreea L StancuDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Eun-Young OhDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Marcello DiStasioDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Vanda TorousDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Benjamin GlassDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Isaac E StillmanDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Stuart J SchnittDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Andrew H BeckDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Edward S BoydenMIT Media Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Cancer Research Institute · USBeth Israel Deaconess Medical Center · USMassachusetts Institute of Technology · USBrigham and Women's Hospital · USInstitute of Biochemistry · ROInstitute of Cognitive and Brain Sciences · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Center for Genomically Engineered OrgansRM1HG008525 · NHGRI · HARVARD MEDICAL SCHOOL · PI CHURCH, GEORGE M · 2015 to 2019
$10.2M
Redesigning General Anesthesia (Admin Supp)R01GM104948 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BOYDEN, EDWARD S., BROWN, EMERY N · 2012 to 2016
$4.4M
High-throughput robotic analysis of integrated neuronal phenotypesR01EY023173 · NEI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BOYDEN, EDWARD S., FOREST, CRAIG · 2012 to 2016
$4.3M
Millisecond-Timescale Whole-Brain Neural Activity Mapping in Health and DiseaseDP1NS087724 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BOYDEN, EDWARD S. · 2013 to 2017
$3.9M
An Accessible Optical Toolbox for Saturated Nanoscale Analysis of Neural ArchitectureR01MH110932 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BOYDEN, EDWARD S., CAI, DAWEN · 2016 to 2019
$2.8M
Ultra-Multiplexed Nanoscale In Situ Proteomics for Understanding Synapse TypesU01MH106011 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BATHE, MARK, BOYDEN, EDWARD S. · 2014 to 2016
$2.2M
Computational pathology to predict breast cancer risk in benign breast diseaseR21CA187642 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SCHNITT, STUART, TAMIMI, RULLA M · 2015 to 2016
$439k
NCATS NIH HHS UL1 TR001102NCI NIH HHS R21 CA187642NEI NIH HHS R01 EY023173NHGRI NIH HHS RM1 HG008525NIGMS NIH HHS R01 GM104948NIMH NIH HHS R01 MH110932NIMH NIH HHS U01 MH106011NINDS NIH HHS DP1 NS087724
6 · The paper itself

Abstract

Expansion microscopy (ExM), a method for improving the resolution of light microscopy by physically expanding a specimen, has not been applied to clinical tissue samples. Here we report a clinically optimized form of ExM that supports nanoscale imaging of human tissue specimens that have been fixed with formalin, embedded in paraffin, stained with hematoxylin and eosin, and/or fresh frozen. The method, which we call expansion pathology (ExPath), converts clinical samples into an ExM-compatible state, then applies an ExM protocol with protein anchoring and mechanical homogenization steps optimized for clinical samples. ExPath enables ∼70-nm-resolution imaging of diverse biomolecules in intact tissues using conventional diffraction-limited microscopes and standard antibody and fluorescent DNA in situ hybridization reagents. We use ExPath for optical diagnosis of kidney minimal-change disease, a process that previously required electron microscopy, and we demonstrate high-fidelity computational discrimination between early breast neoplastic lesions for which pathologists often disagree in classification. ExPath may enable the routine use of nanoscale imaging in pathology and clinical research.

Indexed as

BiopsyBreastFemaleHistological TechniquesHumansImage Processing, Computer-AssistedKidneyMicroscopyMolecular ImagingNanomedicineNephrosis, Lipoid

Identifiers

PMID28714966
PMCPMC5548617
OpenAlexW2735146241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.